Drug Discovery & DDS– category –
-
AlphaFold-Derived Optimized Protein Demonstrates Significant Efficacy in Autoimmune Disease Animal Models, Accelerating AI-Driven Protein Therapeutic Design
bioRxiv Unknown Overview A bioRxiv preprint details preclinical development of a novel therapeutic protein with structure predicted and optimized using AlphaFold. This protein showed remarkable efficacy in animal models of autoimmune dis... -
Recursion Pharmaceuticals Initiates Phase 1 Clinical Trial for AI-Designed Cancer Candidate Drug
ClinicalTrials.gov USA Overview Recursion Pharmaceuticals has registered a novel Phase 1 clinical trial (NCTxxxxxxx) for an AI-designed small molecule cancer candidate drug in patients with advanced solid tumors. This trial will evaluate... -
Insilico Medicine’s AI Platform Identifies Novel Fibrosis Target, Accelerating Preclinical Drug Development
BioRender News USA Overview Insilico Medicine announced its AI-driven drug discovery platform successfully identified a novel therapeutic target for specific fibrotic diseases, validated by in vitro experiments. This high-precision predi... -
Drug Discovery & DDS Weekly Report May 31, 2026
📄 Weekly Report May 31, 2026 (PDF) — Download Weekly Report May 31, 2026 (PDF) — DownloadDownload 🎙 Podcast May 31, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260531.mp3Download -
Regulatory & Policy Shifts Reshape Global Biologics Manufacturing Strategy: Focus on EU Reform, UK Decentralization, and US Tariffs
IMAPAC UK Overview Regulatory and policy shifts, including EU Pharma Reform, UK decentralized manufacturing initiatives, and U.S. tariffs, are fundamentally reshaping global biologics manufacturing strategies. Notably, the UK has establi... -
US Department of Veterans Affairs Launches MDMA-Assisted Mental Health Therapy Trial
VA News (US Department of Veterans Affairs) USA Overview The U.S. Department of Veterans Affairs (VA) has initiated a clinical trial for MDMA-assisted mental health therapy, following the FDA's Breakthrough Therapy designation for MDMA, ... -
WuXi Biologics Intensifies Focus on South Korea to Bolster K-Biotech Partnerships Amid US Pressure
BioCentury (Chosun Biz) South Korea Overview WuXi Biologics is expanding its sales efforts in South Korea, actively targeting K-biotech companies amidst increasing U.S. legislative scrutiny on Chinese biotech firms. As a major global Con... -
WuXi Biologics Shanghai Drug Product Facility Achieves GMP Release, Expands Global Capacity
Contract Pharma China Overview WuXi Biologics' Drug Product Facility 15 (DP15) in Shanghai secured Good Manufacturing Practice (GMP) release in April 2026, becoming its 18th operational drug product facility globally. This state-of-the-a... -
FDA Approves Hepcludex, First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
FDA (Press Release), European AIDS Treatment Group USA Overview The U.S. FDA has approved Hepcludex (bulevirtide-gmod) injection as the first treatment for chronic hepatitis delta virus (HDV) infection in adults, with or without compensa... -
Tuning siRNA Packing Order in Lipid Nanoparticles Controls Oligonucleotide Functional Delivery
bioRxiv (Preprint) International Overview This preprint investigates how tuning the siRNA packing order within lipid nanoparticles (LNPs) can modulate oligonucleotide functional delivery, addressing a key challenge in RNA therapeutics: e...
